(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
04 July 2019 (04.07.2019)

WIPO | PCT

(10) International Publication Number
WO 2019/133817 A1

(51) International Patent Classification:
A61K 47/68 (2017.01) *C07K 16/28* (2006.01)

(21) International Application Number:
PCT/US2018/067868

(22) International Filing Date:
28 December 2018 (28.12.2018)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/611,543 29 December 2017 (29.12.2017) US

(72) Inventor; and
(71) Applicant: **HER, Jeng-Horng** [US/US]; 4760 Castlewood Drive, San Jose, California 95129 (US).

(72) Inventors: **YOU, Jhong-Jhe**; 2F., No.9, Aly. 61, Ln. 200, Yongji Rd., Xinyi Dist., Taipei City, 110 (TW). **HSU, Ching-Hsuan**; 10F., No.151, Guangfeng Rd., Bade Dist., Taoyuan City, 334 (TW). **HUANG, Po-Lin**; 6F., No.69, Donghu Rd., Neihu Dist., Taipei City, 114 (TW). **KAN, Hung-Tsai**; No.9, Ln. 35, Yixing St., Xizhi Dist., New Taipei City, 221 (TW). **CHANG, Ting-Yi**; 3F., No.17, Ln. 31, Sec. 4, Ziqiang Rd., Sanchong Dist., New Taipei City, 241 (TW). **HSIEH, Hsin-Ta**; 7F., No.180, Sec. 1, Tingzhou Rd., Zhongzheng Dist., Taipei City, 100 (TW).

(74) Agent: **MCILVAINE, John, W.** et al.; The Webb Law Firm, One Gateway Center, 420 Ft. Duquesne Blvd., Suite 1200, Pittsburgh, Pennsylvania 15222 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(54) Title: MONOSPECIFIC AND BISPECIFIC PROTEINS WITH IMMUNE CHECKPOINT REGULATION FOR CANCER THERAPY




Fig. 1

(57) Abstract: Provided are monospecific and bispecific proteins that bind specifically to OX40 and/or PD-L1. Exemplary proteins release the inhibition through PD-L1 and stimulate T cell through OX40. Exemplary polyvalent proteins comprise at least one OX40 binding site and at least one PD-L1 binding site. In certain embodiments, the binding sites may be linked through an immunoglobulin constant region. Anti-OX40 and anti-PD-L1 antibodies are also provided.

WO 2019/133817 A1

[Continued on next page]

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*